BIOHAVEN LTD (BHVN) Stock Fundamental Analysis
NYSE:BHVN - New York Stock Exchange, Inc. - VGG1110E1079 - Common Stock - Currency: USD
Taking everything into account, BHVN scores 2 out of 10 in our fundamental rating. BHVN was compared to 560 industry peers in the Biotechnology industry. The financial health of BHVN is average, but there are quite some concerns on its profitability. BHVN is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
BHVN had negative earnings in the past year.
BHVN had a negative operating cash flow in the past year.
In the past 5 years BHVN always reported negative net income.
BHVN had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
The Return On Assets of BHVN (-193.62%) is worse than 88.93% of its industry peers.
With a Return On Equity value of -342.43%, BHVN is not doing good in the industry: 74.64% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -193.62% | ||
| ROE | -342.43% | ||
| ROIC | N/A |
ROA(3y)-101.1%
ROA(5y)-112.04%
ROE(3y)-133.7%
ROE(5y)-344.72%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for BHVN so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
Compared to 1 year ago, BHVN has more shares outstanding
The number of shares outstanding for BHVN has been increased compared to 5 years ago.
BHVN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
Based on the Altman-Z score of -6.14, we must say that BHVN is in the distress zone and has some risk of bankruptcy.
BHVN has a worse Altman-Z score (-6.14) than 64.29% of its industry peers.
There is no outstanding debt for BHVN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -6.14 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
BHVN has a Current Ratio of 2.33. This indicates that BHVN is financially healthy and has no problem in meeting its short term obligations.
BHVN has a worse Current ratio (2.33) than 71.61% of its industry peers.
BHVN has a Quick Ratio of 2.33. This indicates that BHVN is financially healthy and has no problem in meeting its short term obligations.
With a Quick ratio value of 2.33, BHVN is not doing good in the industry: 69.46% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.33 | ||
| Quick Ratio | 2.33 |
3. Growth
3.1 Past
The earnings per share for BHVN have decreased strongly by -37.04% in the last year.
EPS 1Y (TTM)-37.04%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%1.36%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
Based on estimates for the next years, BHVN will show a quite strong growth in Earnings Per Share. The EPS will grow by 13.98% on average per year.
The Revenue is expected to grow by 190.55% on average over the next years. This is a very strong growth
EPS Next Y23.07%
EPS Next 2Y16.34%
EPS Next 3Y14.92%
EPS Next 5Y13.98%
Revenue Next Year240.06%
Revenue Next 2Y289.53%
Revenue Next 3Y291.08%
Revenue Next 5Y190.55%
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
BHVN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BHVN. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
BHVN's earnings are expected to grow with 14.92% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y16.34%
EPS Next 3Y14.92%
5. Dividend
5.1 Amount
BHVN does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
15.06
-0.28 (-1.83%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners89.56%
Inst Owner Change8.32%
Ins Owners11.24%
Ins Owner Change0.15%
Market Cap1.54B
Analysts87.27
Price Target59.4 (294.42%)
Short Float %8.99%
Short Ratio4.38
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-20.46%
Min EPS beat(2)-25.54%
Max EPS beat(2)-15.38%
EPS beat(4)1
Avg EPS beat(4)-35.24%
Min EPS beat(4)-101.89%
Max EPS beat(4)1.84%
EPS beat(8)1
Avg EPS beat(8)-27.54%
EPS beat(12)3
Avg EPS beat(12)-37.32%
EPS beat(16)3
Avg EPS beat(16)-33.19%
Revenue beat(2)0
Avg Revenue beat(2)-100%
Min Revenue beat(2)-100%
Max Revenue beat(2)-100%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-6.2%
PT rev (3m)-10.09%
EPS NQ rev (1m)-0.98%
EPS NQ rev (3m)-13.98%
EPS NY rev (1m)-3.66%
EPS NY rev (3m)-10.47%
Revenue NQ rev (1m)-100%
Revenue NQ rev (3m)-100%
Revenue NY rev (1m)0.65%
Revenue NY rev (3m)-0.7%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 5.93 | ||
| P/tB | 6.42 | ||
| EV/EBITDA | N/A |
EPS(TTM)-9.36
EYN/A
EPS(NY)-6.07
Fwd EYN/A
FCF(TTM)-6.36
FCFYN/A
OCF(TTM)-6.32
OCFYN/A
SpS0
BVpS2.54
TBVpS2.35
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -193.62% | ||
| ROE | -342.43% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-101.1%
ROA(5y)-112.04%
ROE(3y)-133.7%
ROE(5y)-344.72%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 47.02% | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.33 | ||
| Quick Ratio | 2.33 | ||
| Altman-Z | -6.14 |
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)177.45%
Cap/Depr(5y)891.42%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-37.04%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%1.36%
EPS Next Y23.07%
EPS Next 2Y16.34%
EPS Next 3Y14.92%
EPS Next 5Y13.98%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year240.06%
Revenue Next 2Y289.53%
Revenue Next 3Y291.08%
Revenue Next 5Y190.55%
EBIT growth 1Y-70.53%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year17.65%
EBIT Next 3Y7.7%
EBIT Next 5Y16.76%
FCF growth 1Y-100.9%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-103.78%
OCF growth 3YN/A
OCF growth 5YN/A